MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced two novel IRD research programs on gene therapy
MeiraGTx (Nasdaq: MGTX), has announced two pre-clinical programs addressing Inherited Retinal Diseases (IRDs) caused by mutations in KCNV2 and GUCY2D, for cone-dystrophy, and are presented with… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced two novel IRD research programs on gene therapy